Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
Thomas Perkmann, Nicole Perkmann‐Nagele, Thomas Köller, et al.
Microbiology Spectrum (2021) Vol. 9, Iss. 1
Open Access | Times Cited: 176

Showing 1-25 of 176 citing articles:

Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients
Smaragdi Marinaki, Stamatis Adamopoulos, Dimitrios Degiannis, et al.
American Journal of Transplantation (2021) Vol. 21, Iss. 8, pp. 2913-2915
Open Access | Times Cited: 120
Evaluation of antibody response after COVID‐19 vaccination of healthcare workers
Elif Bilge Uysal, Sibel Gümüş, Bayhan Bektöre, et al.
Journal of Medical Virology (2021) Vol. 94, Iss. 3, pp. 1060-1066
Open Access | Times Cited: 75
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations
Maximilian J. Mair, J.M. Berger, Anna S. Berghoff, et al.
JAMA Oncology (2021) Vol. 8, Iss. 1, pp. 106-106
Open Access | Times Cited: 60
Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers
Benjamin Bonnet, Hélène Chabrolles, Christine Archimbaud, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 37
Comprehensive Comparison of Seven SARS-CoV-2-Specific Surrogate Virus Neutralization and Anti-Spike IgG Antibody Assays Using a Live-Virus Neutralization Assay as a Reference
Marianne Graninger, Claudia Jani, Elisabeth Reuberger, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 25
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
Jérôme Barrière, Michel Carlès, Clarisse Audigier-Valette, et al.
European Journal of Cancer (2021) Vol. 162, pp. 182-193
Open Access | Times Cited: 51
Humoral response to SARS-CoV-2 vaccines in people living with HIV
Sebastian Noé, Nino Ochana, Carmen Wiese, et al.
Infection (2021) Vol. 50, Iss. 3, pp. 617-623
Open Access | Times Cited: 48
Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia
Julien Marlet, Philippe Gatault, Zoha Maakaroun, et al.
Vaccines (2021) Vol. 9, Iss. 10, pp. 1055-1055
Open Access | Times Cited: 43
Usefulness of IVD Kits for the Assessment of SARS-CoV-2 Antibodies to Evaluate the Humoral Response to Vaccination
Krzysztof Łukaszuk, Jolanta Kiewisz, Karolina Rozanska, et al.
Vaccines (2021) Vol. 9, Iss. 8, pp. 840-840
Open Access | Times Cited: 41
Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response
Jesús Ontañón, Joaquín Blas, Carlos de Cabo, et al.
EBioMedicine (2021) Vol. 73, pp. 103656-103656
Open Access | Times Cited: 41
mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients
Elena Azzolini, Chiara Pozzi, Luca Germagnoli, et al.
Life Science Alliance (2022) Vol. 5, Iss. 6, pp. e202201381-e202201381
Open Access | Times Cited: 33
Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial
Xuan Ying Poh, Chee Wah Tan, I Russel Lee, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 12, pp. 2088-2096
Open Access | Times Cited: 32
Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
Yandong Shen, Jane A. Freeman, Juliette Holland, et al.
Blood (2022) Vol. 140, Iss. 25, pp. 2709-2721
Open Access | Times Cited: 29
Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study
Daniel Mrak, Elisabeth Simader, Daniela Sieghart, et al.
Annals of the Rheumatic Diseases (2022) Vol. 81, Iss. 12, pp. 1750-1756
Open Access | Times Cited: 28
SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients
Quentin Perrier, Julien Lupo, Théophile Gerster, et al.
Vaccine (2022) Vol. 40, Iss. 44, pp. 6404-6411
Open Access | Times Cited: 28
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants
Trung Tran, Eline Benno Vaage, Adi Mehta, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 28
Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults
Artur Capão, Mia Ferreira de Araújo, Luis Fernando López Tort, et al.
Vaccine (2025) Vol. 50, pp. 126785-126785
Closed Access
Uncertainty quantification of antibody measurements: Physical principles and implications for standardization
Paul N. Patrone, Lili Wang, Sheng Lin‐Gibson, et al.
Physical review. E (2025) Vol. 111, Iss. 2
Closed Access
Lifestyle and Biochemical Parameters That May Hamper Immune Responses in Pediatric Patients After Immunization with the BNT162b2 mRNA COVID-19 Vaccine
Anthie Damianaki, Antonios Marmarinos, Margaritis Avgeris, et al.
Diseases (2025) Vol. 13, Iss. 3, pp. 78-78
Open Access
CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients
Eduard Schulz, Isabel Hodl, Patrick Forstner, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 34
Differential Dynamics of SARS-CoV-2 Binding and Functional Antibodies upon BNT162b2 Vaccine: A 6-Month Follow-Up
Giulia Matusali, Giuseppe Sberna, Silvia Meschi, et al.
Viruses (2022) Vol. 14, Iss. 2, pp. 312-312
Open Access | Times Cited: 25
Cross-Reactivity of SARS-CoV-2 Nucleocapsid-Binding Antibodies and Its Implication for COVID-19 Serology Tests
Alexandra Rak, Svetlana Donina, Yana Zabrodskaya, et al.
Viruses (2022) Vol. 14, Iss. 9, pp. 2041-2041
Open Access | Times Cited: 25
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
Zhigang Liu, Kaixing Le, Xin Zhou, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 2, pp. 145-156
Open Access | Times Cited: 24
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2
Richard Vollenberg, Phil‐Robin Tepasse, Joachim Kühn, et al.
Biomedicines (2022) Vol. 10, Iss. 1, pp. 171-171
Open Access | Times Cited: 23
Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study
Eleni Papadokostaki, Anastasios Tentolouris, Ioanna A. Anastasiou, et al.
Vaccines (2022) Vol. 10, Iss. 3, pp. 382-382
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top